SCHEMBL3675745

SCHEMBL3675745

CC(=O)ON1C(=O)c2ccc(C(=O)OCC(C)C)cc2C1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G1B P04054 1/20 0.53
ATG4B Q9Y4P1 1/20 0.53
LMNA P02545 2/20 0.45
ALDH1A1 P00352 10/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
MAPK1 P28482 1/20 0.44
MAPT P10636 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
KDM4E B2RXH2 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
MET P08581 1/20 0.42
JMJD6 Q6NYC1 1/20 0.41
TP53 P04637 1/20 0.40
TSHR P16473 1/20 0.40
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3681449 0.85 ALDH1A1 (0.58) LMNAALDH1A1MEN1KMT2AMAPK1
SCHEMBL3682116 0.84 ALDH1A1 (0.47) PLA2G1BATG4BALDH1A1MEN1KMT2A
SCHEMBL3676316 0.83 LMNA (0.65) LMNAALDH1A1MEN1KMT2AMAPK1
SCHEMBL3684173 0.83 ALDH1A1 (0.58) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL3675895 0.81 ALDH1A1 (0.67) LMNAALDH1A1MEN1KMT2AMAPK1
SCHEMBL3684899 0.81 ALDH1A1 (0.56) LMNAALDH1A1MEN1KMT2AMAPK1
SCHEMBL3673932 0.80 MAPT (0.60) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL3674677 0.80 ALDH1A1 (0.62) LMNAALDH1A1MEN1KMT2AMAPK1
SCHEMBL3684168 0.79 ALDH1A1 (0.61) LMNAALDH1A1MEN1KMT2AMAPK1
SCHEMBL3682431 0.79 ALDH1A1 (0.61) LMNAALDH1A1MEN1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741514-B2 Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2010-06-22 US disclosed
US-20060281629-A1 Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst ISHII YASUTAKA 2006-12-14 US disclosed
US-7115541-B2 Catalyst comprising n-substituted cyclic imides and processes for preparing organic compounds with the catalyst DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2006-10-03 US disclosed
EP-1338336-A1 CATALYSTS COMPRISING N-SUBSTITUTED CYCLIC IMIDES AND PROCESSES FOR PREPARING ORGANIC COMPOUNDS WITH THE CATALYSTS Daicel Chemical Industries, Ltd. (JP) 2003-08-27 EP disclosed
US-20030013603-A1 Catalyst comprising n-substituted cylic imides and processes for preparing organic compounds with the catalyst DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2003-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281629-A1 Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst NOS2, NOS1, NOS3 PLA2G1B 3609/4885ATG4B 3535/4885LMNA 4170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.